High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study.

MLA

Tedeschi, Alessandra, et al. “High-Dose Idarubicin in Combination with Ara-C in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia: A Pharmacokinetic and Clinical Study.” Cancer Chemotherapy and Pharmacology, vol. 59, no. 6, May 2007, pp. 771–79. EBSCOhost, https://doi.org/10.1007/s00280-006-0332-4.

APA

Tedeschi, A., Montillo, M., Strocchi, E., Cafro, A. M., Tresoldi, E., Intropido, L., Nichelatti, M., Marbello, L., Baratè, C., Camaggi, C. M., & Morra, E. (2007). High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study. Cancer Chemotherapy and Pharmacology, 59(6), 771–779. https://doi.org/10.1007/s00280-006-0332-4

Chicago

Tedeschi, Alessandra, Marco Montillo, Elena Strocchi, Anna Maria Cafro, Elisabetta Tresoldi, Liliana Intropido, Michele Nichelatti, et al. 2007. “High-Dose Idarubicin in Combination with Ara-C in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia: A Pharmacokinetic and Clinical Study.” Cancer Chemotherapy and Pharmacology 59 (6): 771–79. doi:10.1007/s00280-006-0332-4.